CAJ | 학술논문

目的：探讨索拉非尼联合蒽环类化疗药表阿霉素对乳腺癌MCF-7细胞增殖周期的作用。方法细胞做四甲基偶氮唑盐实验，绘制细胞增殖曲线。实验分为4组：对照组、索拉非尼单药组、表阿霉素单药组、联合组(索拉非尼+表阿霉素)。用聚酰亚胺染色后，经流式细胞仪检测各组细胞增殖周期的变化。结果细胞增殖曲线可见细胞传代后开始增殖，4~5d达到峰值，后随着时间的延长，细胞增殖受抑越来越明显。流式细胞仪检测细胞周期结果显示，索拉非尼单药组使MCF-7细胞阻滞于G0/G1期[(62.837±0.511)%]与对照组[(49.250±0.826)%]比较，差异有统计学意义(P<0.05)；表阿霉素单药组使细胞阻滞于S期[(24.976±0.409)%]，与对照组[(23.473±1.009)%]比较，差异有统计学意义(P<0.05)；联合组G0/G1期细胞比率[(64.373±0.429)%]高于对照组及表阿霉素单药组[(50.980±0.403)%]，差异均有统计学意义(均P<0.05)。结论索拉非尼和表阿霉素的联合应用可以使乳腺癌MCF-7细胞明显阻滞于G0/G1，可以为乳腺癌的联合化疗提供一定的理论±据。
목적：탐토색랍비니연합은배류화료약표아매소대유선암MCF-7세포증식주기적작용。방법세포주사갑기우담서염실험，회제세포증식곡선。실험분위4조：대조조、색랍비니단약조、표아매소단약조、연합조(색랍비니+표아매소)。용취선아알염색후，경류식세포의검측각조세포증식주기적변화。결과세포증식곡선가견세포전대후개시증식，4~5d체도봉치，후수착시간적연장，세포증식수억월래월명현。류식세포의검측세포주기결과현시，색랍비니단약조사MCF-7세포조체우G0/G1기[(62.837±0.511)%]여대조조[(49.250±0.826)%]비교，차이유통계학의의(P<0.05)；표아매소단약조사세포조체우S기[(24.976±0.409)%]，여대조조[(23.473±1.009)%]비교，차이유통계학의의(P<0.05)；연합조G0/G1기세포비솔[(64.373±0.429)%]고우대조조급표아매소단약조[(50.980±0.403)%]，차이균유통계학의의(균P<0.05)。결론색랍비니화표아매소적연합응용가이사유선암MCF-7세포명현조체우G0/G1，가이위유선암적연합화료제공일정적이론±거。
Objective To investigate the affect of Sorafenib combined with anthracycline chemotherapy Epirubicin on the proliferation of breast cancer MCF-7 cell cycle. Methods Cells growth curve were drawn after the MTT experiment. Four different groups were set up: control group, Sorafenib group, EPI group and Sorafenib+EPI (combination) group. The change of cell cycles were detected by PI single staining and flow cytometry. Results Cell growth curve showed, passaged cells began to proliferate, and reached the peak after 4-5 days, with the prolongation of time, cell prolifera-tion was inhibited more and more obvious. The cell cycle by flow cytometry showed that, the Sorafenib group [(62.837±0.511)%] induced G0/G1 phase mitosis arrest, compared with control group [(49.250±0.826)%], the difference was statis-tically significant (P<0.05); the EPI group (24.976±0.409)%] induced accumulation of S phase mitosis arrest, com-pared with control group [(23.473±1.009)%], the difference was statistically significant (P< 0.05); and the combination group [(64.373±0.429)%] showed greater increase of G0/G1 phase, compared with control group and EPI group [(50.980±0.403)%], the differences were statistically significant (P< 0.05). Conclusion The combined application of Sorafenib and Epirubicin can make the breast cancer MCF-7 cells arrested in G0/G1, provide certain theoretical basis for the combination chemotherapy for breast cancer.